Press Releases Biora Therapeutics, Inc.

Equities

BIOR

US74319F3055

Market Closed - Nasdaq Other stock markets 01:30:00 27/04/2024 am IST			5-day change	1st Jan Change
0.6277 ^USD	+3.41%		+2.07%	-53.50%

04/04	Biora Therapeutics, Inc. Achieves Positive Interim Results for Clinical Trial of BT-600, Advancing NaviCap Platform Development	CI
03/04	Athyrium Capital Management Engages in Discussions with Biora Therapeutics	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Biora Therapeutics : Form 8937 – Convertible Note Exchange (December 19, 2023)	11/04	PU
Biora Therapeutics Announces New Patent Covering its BioJet™ Liquid Jet Delivery Technology	08/04	AQ
Biora Therapeutics Achieves Positive Interim Results for Clinical Trial of BT-600, Advancing NaviCap™ Platform Development	04/04	AQ
Biora Therapeutics Announces Closing of $6 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules	04/04	AQ
Biora Therapeutics Announces $6 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules	01/04	AQ
Biora Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2023 Financial Results	27/03	AQ
Biora Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Corporate Update	18/03	AQ
Biora Therapeutics Further Reduces Net Debt and Monetizes Legacy Asset	11/03	AQ
Biora Therapeutics Announces Successful Completion of Single-Ascending Dose (SAD) Cohorts of Phase 1 Clinical Study of BT-600	26/02	AQ
Biora Therapeutics Announces Participation in Canaccord Genuity Inflammatory Bowel Disease Symposium	08/02	AQ
Biora Therapeutics Announces Participation in Fireside Chat Hosted by H.C. Wainwright & Co.	22/01	AQ
Biora Therapeutics Provides Outlook for 2024	16/01	AQ
Biora Therapeutics Announces Initiation of Phase 1 Clinical Study of BT-600	08/01	AQ
Biora Therapeutics Progresses Research Collaboration for the BioJet™ Systemic Oral Delivery Platform	02/01	AQ
Biora Therapeutics Announces New Patent for its NaviCap™ Targeted Oral Delivery Platform	19/12	AQ
Biora Therapeutics Accelerates Debt Reduction and Raises Capital with Large Institutional Investors	18/12	AQ
Biora Therapeutics Announces New Research Collaboration for the BioJet™ Systemic Oral Delivery Platform	11/12	AQ
Biora Therapeutics Announces FDA Clearance of IND Application for Drug/Device Combination BT-600 Targeting Treatment of Ulcerative Colitis	01/12	AQ
Biora Therapeutics Provides Corporate Update and Reports Third Quarter 2023 Financial Results	14/11	AQ
Biora Therapeutics to Report Third Quarter 2023 Financial Results and Provide Corporate Update	06/11	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Biora Therapeutics, Inc.

Equities

BIOR

US74319F3055

Press Releases

Filters